Entero Therapeutics, ordinary share
US33749P4081, ENTO

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including ...

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.